Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $0.08 in the last session, down -6.63% from day before closing price of $0.08. In other words, the price has decreased by -$6.63 from its previous closing price. On the day, 26.81 million shares were traded. ADAP stock price reached its highest trading level at $0.083 during the session, while it also had its lowest trading level at $0.0745.
Ratios:
We take a closer look at ADAP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 2.02.
On June 26, 2025, Mizuho Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $0.50.
On July 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $4.H.C. Wainwright initiated its Buy rating on July 30, 2024, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 28 ’25 when EcoR1 Capital, LLC sold 33,931,740 shares for $0.11 per share. The transaction valued at 3,817,321 led to the insider holds 130,492,680 shares of the business.
EcoR1 Capital, LLC sold 27,433,338 shares of ADAP for $2,800,944 on Jul 30 ’25. The 10% Owner now owns 100,371,882 shares after completing the transaction at $0.10 per share. On Jul 29 ’25, another insider, EcoR1 Capital, LLC, who serves as the 10% Owner of the company, sold 2,687,460 shares for $0.10 each. As a result, the insider received 271,971 and left with 127,805,220 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 20541530 and an Enterprise Value of 112391992. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.11. Its current Enterprise Value per Revenue stands at 0.626 whereas that against EBITDA is -3.091.
Stock Price History:
The Beta on a monthly basis for ADAP is 2.26, which has changed by -0.9284404 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, ADAP has reached a high of $1.33, while it has fallen to a 52-week low of $0.07. The 50-Day Moving Average of the stock is -66.66%, while the 200-Day Moving Average is calculated to be -82.32%.
Shares Statistics:
According to the various share statistics, ADAP traded on average about 16.62M shares per day over the past 3-months and 98982150 shares per day over the past 10 days. A total of 257.85M shares are outstanding, with a floating share count of 229.65M. Insiders hold about 10.94% of the company’s shares, while institutions hold 29.76% stake in the company. Shares short for ADAP as of 1752537600 were 3884668 with a Short Ratio of 0.23, compared to 1749772800 on 4563895. Therefore, it implies a Short% of Shares Outstanding of 3884668 and a Short% of Float of 1.78.
Earnings Estimates
The market rating of Adaptimmune Therapeutics Plc ADR (ADAP) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.5 and -$0.5 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.49, with 1.0 analysts recommending between -$0.49 and -$0.49.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $8.96M. It ranges from a high estimate of $12.16M to a low estimate of $6M. As of the current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $128.23MFor the next quarter, 6 analysts are estimating revenue of $12.93M. There is a high estimate of $15.43M for the next quarter, whereas the lowest estimate is $9.03M.
A total of 4 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $54.1M, while the lowest revenue estimate was $32.7M, resulting in an average revenue estimate of $48.24M. In the same quarter a year ago, actual revenue was $178.03MBased on 5 analysts’ estimates, the company’s revenue will be $67.37M in the next fiscal year. The high estimate is $85M and the low estimate is $41.4M.
